timothy sykes logo
ALNY Stock Rebounds As Analysts Back RNAi Growth Story Thumbnail
G Google News

ALNY Stock Rebounds As Analysts Back RNAi Growth Story

ELLIS HOBBS•UPDATED SEP. 2, 2026, 12:32 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Alnylam Pharmaceuticals Inc. stocks have been trading up by 7.5 percent after pivotal positive clinical trial results boosted investor optimism.

Key Takeaways

  • Wall Street desks are leaning bullish on ALNY after a sharp pullback, with multiple firms highlighting upside driven by its ATTR and RNAi pipeline.
  • Several banks trimmed long-term TTR revenue expectations yet kept positive ratings, framing the reset as a new base rather than a broken story.
  • A U.S. Department of Veterans Affairs deal worth up to $387.84M adds a meaningful, government-backed revenue stream for Alnylam.
  • Fresh ESC Congress 2026 data show AMVUTTRA, patisiran, and zilebesiran delivering strong, consistent cardiovascular and ATTR results.
  • Updated data also strengthened Oppenheimer’s view on Nucresiran and the TRITON-CM trial, pointing to higher success odds and near-term upside.

Candlestick Chart

Live Update At 12:32:18 EDT: On Wednesday, September 02, 2026 Alnylam Pharmaceuticals Inc. stock [NASDAQ: ALNY] is trending up by 7.5%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ALNY has been grinding higher over the past couple of weeks. From a close near $216.98 on 2026/08/10, Alnylam has pushed up into the mid-$260s, finishing the latest session around $264.56 after touching an intraday high of $269.10. That is a strong bounce from the $220–$230 area and shows dip buyers are active again.

On the 5‑minute chart, ALNY opened at $246.48 and ripped quickly into the mid‑$250s, then stair‑stepped higher through the morning toward $269 before cooling off in the afternoon. That intraday range shows aggressive trading and decent liquidity for short‑term setups.

Fundamentally, Alnylam is a high‑growth, high‑expectation biotech. Revenue over the last year is about $3.71B, with monster 3‑year and 5‑year revenue growth of 57.17% and 47.52%. Gross margin near 92.1% tells traders this is a premium drug portfolio with strong pricing power.

More Breaking News

The flip side: ALNY trades at a rich price‑to‑sales around 6.7 and a P/E near 40.93, so the market already bakes in big future success. The balance sheet is solid, with a current ratio of 3.1 and manageable leverage. For traders, ALNY is a classic story stock: expensive on today’s numbers, driven by pipeline, data, and headlines.

Why Traders Are Watching ALNY Right Now

What really has ALNY back on screens is the one‑two punch of bullish data and bullish analyst commentary after a brutal drawdown. Raymond James upgraded Alnylam to Strong Buy with a $420 target after the stock dropped about 35% since early July. Their point: at those lower levels, ALNY was priced as if its transthyretin (TTR) franchise had already flopped and the broader RNAi pipeline was worth almost nothing. That kind of disconnect is exactly what active traders hunt.

BMO Capital piled on with new coverage, slapping an Outperform rating and a $318 target on ALNY. BMO framed the post‑guidance weakness as an attractive entry, leaning on strong ATTR growth and the depth of Alnylam’s RNAi platform. When new coverage starts positive right after a disappointment, it often signals that the Street thinks the worst headlines are out.

Yes, Alnylam did reset expectations. H.C. Wainwright cut its ALNY target to $455 from $485 after the company lowered 2026 TTR product revenue guidance by roughly $200M. Barclays trimmed its target to $450 from $527 following a weak quarter, warning that Amvuttra’s growth now depends on expanding the prescriber base. But notice the pattern: targets down, ratings still bullish. Wainwright still sees more than 100% upside from the post‑selloff levels. Barclays kept an Overweight call.

Layer in real business wins. ALNY secured a Department of Veterans Affairs contract worth up to $387.84M. For traders, that is not just a headline; it is a multi‑year, government‑backed revenue pipeline that helps stabilize the story while the market digests the TTR reset.

On top of that, ESC Congress 2026 data gave ALNY’s narrative fresh fuel. AMVUTTRA (vutrisiran) and patisiran showed strong, consistent benefits across ATTR‑CM and hATTR‑PN subgroups, even in patients already on tafamidis. Zilebesiran delivered Phase 2 subgroup data strong enough to support a Phase 3 push in uncontrolled hypertension, with the ZENITH CV‑outcomes trial already rolling. Oppenheimer leaned on these updates to reinforce its Outperform rating and a $350 target, saying the new data lift the odds of success for Nucresiran and the TRITON‑CM trial and create near‑term upside as ESC event risk fades.

Put together, ALNY sits at the intersection of chart momentum, analyst support, and high‑impact clinical news — the exact mix momentum traders look for.

Conclusion

For traders, ALNY is not a sleepy pharma name; it is a volatile biotech with real catalysts and real risk. The stock just bounced from the low‑$220s into the mid‑$260s as the market re‑priced Alnylam’s future after that 35% drawdown. Analyst targets from $318 at BMO, $350 at Oppenheimer, $420 at Raymond James, and $450–$455 from Barclays and H.C. Wainwright sketch a wide, bullish band above current prices, built on confidence in the ATTR franchise and the broader RNAi pipeline.

At the same time, the guidance cut on 2026 TTR revenue and the reliance on execution — especially expanding Amvuttra’s prescriber base — keep ALNY firmly in “story stock” territory. New ESC Congress 2026 data on AMVUTTRA, patisiran, zilebesiran, and Nucresiran, plus the VA contract up to $387.84M, add real weight to that story, but traders still have to respect headline risk and trial risk.

This is where the Sykes‑style playbook matters. As Tim Sykes likes to say, “The market rewards the prepared, not the hopeful — study the catalysts, plan every trade, and cut losses ruthlessly.” As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. For ALNY, that means knowing the clinical calendar, tracking how the chart reacts to each data drop, and treating every entry and exit as a planned trade, not a hope trade. This article is for educational and research purposes only and is not advice; use it as a starting point for your own deep dive before risking real capital on ALNY.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”